Boundless Bio (BOLD) Free Cash Flow (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Free Cash Flow of -$15.0 million for Q1 2026, down 2.87% year-over-year from -$15.5 million in Q1 2025, and down 41.99% quarter-over-quarter from -$10.6 million in Q4 2025.
Boundless Bio (BOLD) Free Cash Flow (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Free Cash Flow for 4 consecutive years, with -$15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 2.87% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$47.7 million (up 20.52% YoY), while the FY2025 annual figure was -$47.2 million, up 22.85% from the prior year.
- Free Cash Flow declined to -$15.0 million in Q1 2026 per BOLD's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$10.2 million in Q3 2025 and bottomed at -$17.7 million in Q2 2024.
- Historically, Free Cash Flow has averaged -$13.2 million across 4 years, with a median of -$12.3 million in 2023.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 60.14% — and 2025, when it soared 32.82%.
- Boundless Bio's Free Cash Flow stood at -$12.0 million in 2023, then retreated by 16.22% to -$13.9 million in 2024, then gained by 23.92% to -$10.6 million in 2025, then sank by 41.99% to -$15.0 million in 2026.
- Business Quant data shows BOLD's Free Cash Flow at -$15.0 million in Q1 2026, -$10.6 million in Q4 2025, and -$10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 477.44 Mn |
| 10 | Boundless Bio | 66.79 Mn | 66.79 Mn | - | -20.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.98 Mn |
| Jun 30, 2026 | -20.98 Mn |
| Mar 31, 2026 | -15.01 Mn |
| Mar 31, 2026 | -15.01 Mn |
| Dec 31, 2025 | -10.57 Mn |
| Dec 31, 2025 | -10.57 Mn |
| Sep 30, 2025 | -10.17 Mn |
| Sep 30, 2025 | -10.17 Mn |
| Jun 30, 2025 | -11.92 Mn |
| Jun 30, 2025 | -11.92 Mn |
| Mar 31, 2025 | -14.59 Mn |
| Mar 31, 2025 | -14.59 Mn |
| Dec 31, 2024 | -13.89 Mn |
| Dec 31, 2024 | -13.89 Mn |
| Sep 30, 2024 | -13.75 Mn |
| Sep 30, 2024 | -13.75 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -15.86 Mn |
| Mar 31, 2024 | -15.86 Mn |